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Abstract
Objectives: Head and neck cancer (HNC) diagnosis through the 2-week wait, urgent 
suspicion of cancer (USOC) pathway has failed to increase early cancer detection 
rates in the UK. A head and neck cancer risk calculator (HaNC-RC) has previously 
been designed to aid referral of high-risk patients to USOC clinics (predictive power: 
77%). Our aim was to refine the HaNC-RC to increase its prediction potential.
Design: Following sample size calculation, prospective data collection and statistical 
analysis of referral criteria and outcomes.
Setting: Large tertiary care cancer centre in Scotland.
Participants: 3531 new patients seen in routine, urgent and USOC head and neck 
(HaN) clinics.
Main outcome measures: Data collected were as follows: demographics, social his-
tory, presenting symptoms and signs and HNC diagnosis. Univariate and multivari-
ate regression analysis were performed to identify significant predictors of HNC. 
Internal validation was performed using 1000 sample bootstrapping to estimate 
model diagnostics included the area under the receiver operator curve (AUC), sensi-
tivity and specificity.
Results: The updated version of the risk calculator (HaNC-RC v.2) includes age, gen-
der, unintentional weight loss, smoking, alcohol, positive and negative symptoms and 
signs of HNC. It has achieved an AUC of 88.6% with two recommended triage refer-
ral cut-offs to USOC (cut-off: 7.1%; sensitivity: 85%, specificity: 78.3%) or urgent 
clinics (cut-off: 2.2%; sensitivity: 97.1%; specificity of 52.9%). This could redistribute 
cancer detection through USOC clinics from the current 60.9%–85.2%, without af-
fecting total numbers seen in each clinical setting.
Conclusions: The use of the HaNC-RC v.2 has a significant potential in both identify-
ing patients at high risk of HNC early thought USOC clinics but also improving health 
service delivery practices by reducing the number of inappropriately urgent referrals.
2  |     TIKKA eT Al.
1  | INTRODUC TION
The cancer treatment outcomes in the UK have been persistently 
lower than many countries in Europe as has been highlighted in the 
EUROCARE cancer studies.1,2 It has been suggested that this may be 
due to the delays in cancer detection, with patients presenting in ad-
vanced cancer stages.3 Head and neck cancer (HNC) is the 8th most 
common cancer in the UK with a continuing rise in its incidence.4 
Previous audits from England and Ireland showed that the majority 
of cancers are diagnosed at a disease stage III or IV.4,5 21% of HNC 
patients visited their GP more than twice prior to being diagnosed 
with cancer.6
In the recent years, there has been a drive for the development 
of risk calculators designed to identify cancer at early stages. This 
is an area of great opportunity for improvement of patients' cancer 
journeys from initial presentation in primary care, to diagnosis in the 
hospital setting and initiation of treatment.7 At present, several risk 
calculators are available for common cancers, such as prostate, lung 
or ovarian cancer, which have been externally validated and are rec-
ommended for use to aid prompt referral of high-risk individuals to 
specialist clinics for further assessment.8 However, most of these 
normograms require results of blood tests and radiological findings—
in addition to patients' symptoms and demographics—to calculate 
cancer probability, which potentially limits their widespread adop-
tion in the primary care settings.9 On the other hand, there are also 
examples where risk can be established solely on the basis of symp-
toms and demographics, such as for lung and colorectal cancer.10-12
Risk calculators do not only have the potential to contribute to 
earlier diagnosis of cancers but could also lead to service delivery 
improvements. Only 35%-38% of HNC in the UK are currently diag-
nosed via the 2-week wait pathway, with the rest of cases identified 
in other types of outpatient appointments or emergency admis-
sions.13 With an average of 100 000 HNC urgent suspicion of cancer 
(USOC) referrals annually in the UK14 and an annual HNC incidence 
of 12 000,4 one can extrapolate a UK-wide USOC HNC conversion 
rate of 4.3%. A review of the literature has highlighted a large num-
ber of inappropriate USOC referrals and an average HNC diagnosis 
of only 8%.15,16
The above underline the importance of early HNC diagnosis 
and the need for change of the current referral pathways. Although 
cancer risk calculators have been available for the last 10-20 years 
for other common cancers, prediction models for HNC have only 
recently started to emerge. The first head and neck cancer risk cal-
culator (HaNC-RC) in 2016 based on patients' symptoms, signs and 
demographics using data from 4715 patients seen in USOC clinics 
from Birmingham and Newcastle (area under the receiver opera-
tor characteristic curve [AUC]: 0.77; sensitivity: 74.8%, specificity: 
65.9%).16 The variables included in the model are available in Table 1. 
It was subsequently externally validated with a cohort from a differ-
ent UK region (Glasgow), yielding an AUC of 0.81, combined with 
high sensitivity (79.3%) and specificity (68.6%).17 Another calculator 
was proposed by a different research group, applying an alternative 
symptom combination, demographics as well as smoking and alcohol 
data based on a cohort of 1075 USOC referrals (Table 1). Although 
the AUC was high at 0.79, the sensitivity was low at 31% with high 
false negative figures in their external validation cohort.18 Artificial 
intelligence methods have also been attempted for the development 
of HNC risk calculators with the variation logistic regression being 
suggested the most effective method.19 (Table 1).
Current trends in this area lean towards validation of existing 
normograms, combined with continuous improvement through fur-
ther iterations for increased predictive power instead of continuous 
generation of new prediction models.20 The aim of this study was 
therefore to attempt to further increase the predictive power of the 
HaNC-RC by assessing the potential for inclusion of other signifi-
cant symptoms (such as weight loss, neck pain and sore throat), the 
refinement of symptoms already in the model (addition of symptom 
laterality and persistency) and the addition of social history factors 
(smoking, alcohol).
2  | METHODS
Data were collected prospectively from new patients seen in 
all types of head and neck (HaN) clinics (USOC, urgent, routine) 
from January 2017 until December 2018 in hospitals covering 
the Greater Glasgow and Clyde region. Sample size calculation 
indicated that assuming the lowest estimated disease prevalence 
which currently sits at 8% amongst symptomatic individuals re-
ferred by their GP to suspicion of cancer clinics, to demonstrate 
test performance of at least 80% sensitivity and 75% specificity 
to within ±5% with 80% power. The sample was initially collected 
on all referrals, but after the first 18 months of data collection, 
the cancer incidence was lower than the expected 8% (aiming for 
>300 cancer cases) whilst reaching saturation of the non-cancer 
referrals symptoms. Hence data collection continued only for 
Keypoints
• The majority of head and neck cancers (HNC) in the 
UK are diagnosed via non urgent suspicion of cancer 
(USOC) routes.
• A head and neck cancer risk calculator was created in 
2016 to identify individuals at high risk of HNC for a 
USOC referral.
• The calculator is now updated (HaNC-RC v.2) with inclu-
sion of social history factors, further significant symp-
toms and refinement of previously included symptoms.
• HaNC-RC v.2 has a higher predictive power; sensitivity 
and specificity compared with its previous version.
• It is envisaged that the HaNC-RC v2 will be used to ef-
fectively triage patients to routine, urgent and USOC 
clinics to reduce cancer waiting times and increase HNC 
diagnosis though the USOC pathway.
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patients with a cancer diagnosis until the targeted number of can-
cer cases was reached (n = 77 additional cancer cases), in order to 
boost cancer numbers to enable better prediction using logistic 
regression analysis modelling. This resulted in a total number of 
3531 cases and 307 cancers, with no missing data, for statistical 
analysis. The HNC incidence, cancer diagnosis per clinic appoint-
ment, calculation of negative predictive value (NPV), positive pre-
dictive value (PPV) and suggested re-triaging following the risk 
calculator development were calculated in the un-boosted can-
cer cohort to ensure non-contamination of sample from cancer 
boosting. Table 2 summarised the data collection proforma. The 
HNC diagnosis included all primary cancers to the HaN regions 
(n = 247), metastatic cancers to the HaN from other regions, in-
cluding lymphoma (n = 48) and cancers in neighbouring regions 
that manifested with HaN symptoms (n = 12).
2.1 | Statistical analysis
Univariable logistic regression analysis was performed to identify 
significant variables for potential inclusion in the multivariate anal-
ysis. All variables that reached the α = .1 level of significance were 
screened for potential inclusion including any possible two-way 
interactions of these variables which met the stricter threshold for 
TA B L E  1   Suggested models for triaging of HNC referrals
Publication Variables Model statistics
Tikka et al, 2016 Age Model build: Logistic regression
Gender Population: USOC referrals
Persistent hoarseness >3 wk Sensitivity:74.8%
Oral ulcer >3 wk Specificity: 65.9%
Oral swelling >3 wk AUC: 0.77
Persistent dysphagia >3 wk Probability Cut-off: 8%
Neck lump >3 wk External validation
Haemoptysis AUC: 0.81
Feeling of lump in throat Sensitivity: 79.3%
Recent unexplained neck lump (<3 wk) Specificity: 68.6%
Unexplained otalgia  
Intermittent hoarseness  
Odynophagia  
Lau et al, 2018 Age Model build: Logistic regression
Smoking pack years Population: USOC referrals
Alcohol units over RWI Sensitivity: 31%
Oral ulcer Specificity: 92%
Neck lump AUC: 0.79
Ear lesion Probability cut-off: not mentioned
Facial lesion
Tongue ulcer
Weight loss
Unilateral hearing loss External validation: Not performed
Thyroid swelling  
Moor et al, 2019 Variables included not mentioned Model build: Different machine learning techniques.
 Population: USOC referrals
Best performance: Variational logistic regression
True negative rate (specificity): 25.8 ± 8.9
False negative rate: 0.1 ± 0.16
False positive rate: 66.4 ± 8.9
True positive rate (sensitivity): 7.7 ± 1.4
AUC, probability thresholds, sensitivity, specificity: 
Not mentioned
External validation: No
4  |     TIKKA eT Al.
inclusion using the Bonferroni correction (α = .1/number of inter-
actions tested). Backwards elimination was undertaken to identify 
a parsimonious model with each of the finally included variables 
having a P value of α = .05 or less. Internal validation of the final 
model was performed using 1000 bootstrap samples each per-
forming random splits of the data set into training and validation 
sets with a final generation of the estimated mean AUC across 
each of the 1000 validation sets. The suggested probability cut-
off for a USOC referral was selected to be the probability value 
that generated the highest value combination of sensitivity and 
specificity simultaneously. Following exclusion of the USOC cases, 
a second threshold was calculated using the same principle for the 
rest of the referrals, with those above the recommended cut-off 
being considered for an urgent (6 weeks) appointment. Chi-square 
analysis was performed to compare the distribution of HNC diag-
nosis based on the current GP triaging and the one generated im-
plementing the USOC and urgent thresholds on our data set. For 
the reclassification of referrals, the true incidence of cases was 
used; hence, the un-boosted cancer cases were used (n = 230) and 
for the calculation of the NPV and PPV based on the USOC cut-off. 
AUC, sensitivity and specificity values were also calculated using 
the previous version of the HaNC-RC for comparisons to the latest 
version. The R and SPSS statistical software were used for data 
analysis. The R libraries used for prediction and AUC were as fol-
lows: Epi; ROCR; Deducer.
2.2 | Ethical considerations
The data reported by the clinicians in the clinical notes did not de-
viate from standard practice. No ethics committee approval was 
therefore required for this study. Instead, the project was registered 
with Caldicott guardian of the NHS Greater Glasgow and Clyde 
(GGC/07/02/17) as quality improvement project. No patient identi-
fiable information was included in the database.
3  | RESULTS
The data set included a total of 3650 patients seen in HNC clinics 
during the 18 months period. There were missing data for 119 pa-
tients who were excluded from any further analysis. 1067 (30.2%) 
of the 3531 patients were referred in the USOC clinics. 307 (8.7%) 
patients were diagnosed with HNC but only 59.9% of these were 
 
Head and neck cancer
OR (95% CI) P value *Yes No
Gender
Males 208 (14.3%) 1246 (85.7%) 3.34 (2.6-4.9) .0001
Females 99 (4.8%) 1978 (95.2%)
Age
Mean (SD) 63.7 (9.1) 57 (16.9) 1.03 (1.02-1.03) .0001
Smoking
Current 145 (16.3%) 744 (83.7%) Current vs never: 3.8 
(2.9-5.1)
.0001
Ex 85 (8.1%) 963 (91.9%) Ex vs never: 1.7 (1.3-2.4)
Never 77 (4.8%) 1517 (95.2%)
Alcohol
>14 units/week 85 (20.6%) 327 (79.4%) >14 u/w vs <=14 u/w: 
5.4 (3.4-8.3)
.001
Previous excess 30 (26.8%) 82 (73.2%) Ex excess vs <=14u/w: 
3.8 (2.9-5.0)
≤14 units/week 192 (6.4%) 2815 (93.6%)
Abbrevaitions: CI, confidence interval; OR, odds ratio.
*Univariable binary logistic regression. 
TA B L E  3   Patients demographics, 
smoking and alcohol as risks factors for 
head and neck cancer
TA B L E  2   Pre-agreed data collection proforma
Data collection proforma
Age
Gender (male, female)
Smoking (current, ex-smoker, non-smoker)
Alcohol (>14 unit/week, ≤14 units/week, previous excess)
Unintentional weight loss
Any presenting symptoms with mention of duration, laterality, 
persistency
Any presenting signs (findings during examination of neck with 
palpation, examination of oral cavity and oropharynx with head 
light and tongue depressor and inspection of skin of head and 
neck for any lesions including anterior rhinoscopy with a nasal 
speculum)—flexible endoscopy finding not included.
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diagnosed through the USOC route. The HNC incidence (un-boosted 
cohort) was 6.66% (n = 230).
The majority of patients were female (n = 2077, 58.8%). The 
mean age was 57.2 (SD:16.8). 889 (25.2%) were current smokers. 
Alcohol was consumed in excess by 11.7% of patients (n = 412) 
TA B L E  4   Patient presenting complaints and symptoms
 
Head and neck cancer
P 
value*Yes No
Unintentional weight loss
Yes 71 (25.7%) 205 (74.3%) .0001
No 236 (7.3%) 3019 (92.7%)
Hoarseness
Persistent 75 (20.1%) 299 (79.9%) .0001
Intermittent 13 (1.9%) 655 (98.1%)
Persistent explained 
(after URTI/stroke/
surgery/voice use 
excess at work or 
hobby)
3 (3.7%) 79 (96.3%)
No 216 (9%) 2191 (91%)
Sore throat
Persistent bilateral/
midline
32 (20.9%) 121 (79.1%) .0001
Persistent unilateral 24 (53.3%) 21 (46.7%)
Intermittent bilateral/
midline
3 (1.3%) 98.7%)
Intermittent unilateral 1 (4.3%) 22 (95.7%)
No 247 (8%) 2825 (92%)
Throat discomfort/irritation
Yes 16 (6.2%) 242 (93.8%) .142
No 291 (8.9%) 2982 (91.1%)
Feeling of something in throat (FOSIT)
Yes 9 (1.5%) 578 (98.5%) .0001
No 298 (10.1%) 2646 (89.9%)
Dysphagia
Persistent 70 (28.5%) 176 (71.5%) .0001
Intermittent 4 (1.6%) 253 (98.4%)
No 233 (7.7%) 2795 (92.3%)
Regurgitation
Yes 8 (7.5%) 99 (92.5%) .650
No 299 (8.7%) 3125 (91.3%)
Odynophagia
Yes 38 (48.1%) 41 (51.9%) .0001
No 269 (7.8%) 3183 (92.2%)
Neck pain
Persistent bilateral/
midline
8 (16.7%) 40 (83.3%) .364
Persistent unilateral 6 (10.5%) 51 (89.5%)
Intermittent bilateral/
midline
0 39 (100%)
Intermittent unilateral 2 (5.4%) 35 (94.6%)
No 291 (8.7%) 3059 (91.3%)
(Continues)
 
Head and neck cancer
P 
value*Yes No
Neck lump
Persistent 144 (17.5%) 681 (82.5%) .0001
Intermittent/
regressing
8 (2.9%) 270 (97.1%)
No 155 (6.4%) 2273 (93.6%)
Choking episodes/feeling
Yes 8 (4.5%) 168 (95.5%) .05
No 299 (8.9%) 3056 (91.1%)
Catarrh/mucus
Yes 1 (0.7%) 135 (99.3%) .01
No 306 (9%) 3089 (91%)
Blocked nose
Unilateral 0 8 (100%) .999
Bilateral 0 22 (100%)
No 307 (8.8%) 3194 (91.3%)
Oral swelling
Yes 55 (32.5%) 114 (67.5%) .0001
No 252 (7.5%) 3110 (92.5%)
Oral ulcer
Yes 12 (48%) 13 (52%) .0001
No 295 (8.4%) 2311 (91.6%)
Heamoptysis
Yes 11 (14.5%) 65 (85.5%) .075
No 296 (8.6%) 3159 (91.4%)
Unexplained unilateral otalgia (normal otoscopy)
Yes 28 (29.2%) 68 (70.8%) .0001
No 279 (8.1%) 3156 (91.9%)
Face pain/numbness
Yes 0 27 (100%) .998
No 307 (8.7%) 3197 (91.2%)
Noisy breathing/stridor
Yes 6 (50%) 6 (50%) .0001
No 301 (8.6%) 3218 (91.4%)
Red/white patch in mouth
Yes 2 (4.7%) 41 (95.3%) .353
No 305 (8.7%) 3183 (91.3%)
Persistent head and neck skin lesion
Yes 8 (21.1%) 30 (78.9%) .009
No 299 (8.6%) 3194 (91.4%)
*Univariable binary regression analysis 
TA B L E  4   (Continued)
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using the UK government recommendation of 14 units of alco-
hol per week as the recommended limit. The significance of the 
above demographics in HNC diagnosis on univariable analysis is 
presented in Table 3.
The most common presenting symptom was hoarseness 
(n = 1124, 31.8%), followed by presence of a neck lump (n = 1103, 
31.2%). Table 4 summarises presenting symptoms, sub-grouped for 
cancer diagnosis and the univariable logistic regression findings. All 
TA B L E  5   Multivariable binary logistic regression of the final selected model
Variable Estimate SE P value Odds ratio (95% CI)
Intercept −6.890 0.433 <.0001  
Age 0.028 0.005 <.0001 1.029 (1.018-1.398)
Gender
Male vs female 1.031 0.163 <.0001 2.805 (2.043-3.872)
Unintentional weight loss
Yes vs no 0.778 0.228 .0006 2.178 (1.384-3.383)
Smoking
Yes vs no 0.602 0.188 .0001 1.827 (1.265-2.645)
Ex vs no 0.360 0.191 .0588 1.434 (0.986-2.085)
Alcohol
>14 units/week vs ≤14 units/week 0.753 0.194 .0001 2.123 (1.446-3.098)
Ex excess vs ≤14 units/week 0.545 0.313 .0814 1.725 (0.919-3.145)
Hoarseness
Persistent vs no 1.813 0.227 <.0001 6.129 (3.942-9.593)
Intermittent vs no −0.188 0.338 .5791 0.829 (0.408-1.556)
Explained persistent vs no 0.384 0.668 .5651 1.469 (0.315-4.682)
Sore throat
Persistent bilateral/midline vs no 0.767 0.311 .0136 2.154 (1.152-3.907)
Persistent Unilateral vs no 2.269 0.489 <.0001 9.678 (3.671-25.069)
Intermittent bilateral/midline vs no −1.124 0.614 .0670 0.325 (0.077-0.924)
Intermittent unilateral vs no 0.1501 1.114 .8929 1.162 (0.058-7.029)
FOSIT
Yes vs no −1.209 0.399 .0025 0.298 (0.127-0.615)
Dysphagia
Persistent vs no 1.266 0.245 <.0001 3.547 (2.182-5.719)
Intermittent vs no −1.206 0.574 .0357 0.299 (0.082-0.813)
Odynophagia
Yes vs no 2.604 0.216 <.0001 13.522 (6.033-30.536)
Neck lump
Persistent vs no 2.424 0.216 <.0001 11.288 (7.447-17.395)
Intermittent/regressing vs no 0.541 0.429 .2071 1.718 (0.691-3.785)
Oral swelling
Yes vs no 2.251 0.267 <.0001 9.502 (5.631-16. 071)
Oral ulcer
Yes vs no 1.903 0.585 .0001 6.707 (2.107-20.995)
Unilateral otalgia with normal otoscopy
Yes vs no 1.169 0.355 .0009 3.220 (1.588-6.401)
Stridor
Yes vs no 2.307 0.914 .0116 10.049 (1.414-57.132)
Persistent head and neck skin lesion
Yes vs no 2.193 0.475 <.0001 8.963 (3.358-22.0677)
Abbrevaitions: FOSIT, feeling of something in throat; SE, standard error.
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symptoms were present for at least 3 weeks. Multivariate regression 
analysis identified 12 symptoms as significant predictors of HNC. 
Patients' demographics, alcohol and smoking status were also signif-
icant factors. Table 5 shows the variables included in the new ver-
sion of the HaNC-RC (v.2). None of the 2-way interactions reached 
the Bonferroni corrected threshold for significance. The predictive 
power of the model calculated by the area under the receiver oper-
ation curve (AUC) following internal validation was 0.8856; 95% CI: 
0.8818-0.8879.
The 0.071 probability cut-off maximised sensitivity and spec-
ificity at the same time, and it is recommended as a cut-off point 
for referral of patients in the USOC (sensitivity: 85%, specificity: 
78.3%). The PPV was 20.7%, and the NPV was 98.6%. For health-
care systems that have a second clinic classification on 4 weeks ur-
gency, a second cut-off was generated at 0.022 with a sensitivity 
of 97.1% and a specificity of 52.9% that maximised again sensitivity 
and specificity after cases of probability of more than .071 were ex-
cluded. Finally, the sensitivity and specificity results of the revised 
calculator were compared with the output of the previous version 
of the calculator using our current cohort. Applying the older ver-
sion of the HaNC-RC, the sensitivity dropped by 5%-80.78% and 
specificity by 10%-68.08%, with an AUC of 0.801. Hence, a head to 
head comparison of the diagnostic power for the first and second 
version of the calculator showed improved sensitivity and specific-
ity values.
We modelled the potential impact the calculator could have on 
patient referral. Table 5 shows how the HaNC-RC v.2 would have 
redistributed patients to clinics, including the resulting impact on 
cancer detection per clinic type. The calculations were based on 
the un-boosted cancer population. The data suggest that the num-
ber of patients diagnosed in clinics is significantly reduced from 
39.1% (26.1% in urgent clinics; 13% in routine) to 14.8% (12.2% in 
urgent, 2.6% in routine) whilst the cancer detection from the USOC 
clinics would be significantly increased from 60.9% to 85.2%. The 
change in the cancer diagnosis using the HaNC-RC v2 re-triaging 
was statistically significant (P < .0001), and this could occur whilst 
seeing less patients through the USOC and urgent route (Table 6).
An online calculator to measure the HNC probability of a patient 
presenting with the symptoms and signs of the HaNC-RC v2 is avail-
able online at http://orlhe alth.com/risk-calcu lator-2.html.21
4  | DISCUSSION
4.1 | Synopsis of new findings
Our study increased the predictive power of the previous 
HaNC-RC (v.1) from 77%16 to 88.6%. The HaNC-RC v.2 includes 
smoking (current, ex-smoker and non-smoker) and alcohol history 
(>14 units/week, ≤14 units/week, previous excess), data that were 
not available in the previous iteration of the calculator. We also 
included in the updated version new significant symptoms: sore 
throat (to include persistency and laterality), unintentional weight 
loss, stridor, HaN skin lesion, and we refined symptoms already 
in the risk calculator (hoarseness—accounting for persistency and 
previous relevant history, dysphagia and neck lump—to include 
persistency). By including intermittent/persistent and unilateral/
bilateral-midline, we accounted for the varying presentation of 
common HaN symptoms.
The previous version of the calculator included significant inter-
actions between negative and positive symptoms for cancer which 
did not significantly alter the prediction power of the calculator 
this time; hence, they were dropped from the revised model. This 
reflects the fact that stronger predictors are now included in the 
HaNC-RC v.2.
Our study has also demonstrated that it is possible for most HNC 
patients to be diagnosed through USOC clinics by triaging their re-
ferral using the HaN-RC v.2. The cancer detection in the USOC clin-
ics could have increased from the current pick up rate of 60.9% to 
85.2%, with only 2.6% of cancer having delayed detection in routine 
clinics compared with the current figure of 13%. With waiting times 
for a routine appointment currently being in the region of 3 months 
to up to more than 25 weeks in some regions,13,14 this can translate 
in a significant reduction of the time from referral to cancer diagno-
sis. The improved figures could be obtained without increasing the 
number of patients seen in the USOC clinics.
4.2 | Comparison with other studies
The new variables included in the HaNC-RC v.2 are supported by 
previous cohort studies in the USOC referrals in which univariate 
TA B L E  6   Cancer detection in head and neck clinics with current triage system compared with suggested HaNC-RC v2 triaging (USOC 
referral: for probability cut-offs ≥0.071, urgent referrals: probability cut-offs 0.022- 0.0709; routine referrals <.022)
 
Current triaging pathway
(GP referrals)
Total
Suggested triaging
(HaNC-RC v2)
Total
Cancer Cancer
Yes No Yes No
Routine 30 (13%) 1339 (41.5%) 1369 (39.6%) 6 (2.6%) 1625 (50.4%) 1631 (47.2%)
Urgent 60 (26.1%) 1002 (31.1%) 1062 (30.7%) 28 (12.2%) 849 (26.3%) 877 (25.4%)
USOC 140 (60.9%) 883 (27.4%) 1023 (29.6%) 196 (85.2%) 750 (23.3%) 946 (27.4%)
Note: Data reflect true cancer incidence per clinic type from the un-boosted cancer population.
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analysis was performed to identify significant cancer predictors such 
as unintentional weight loss, smoking and alcohol.16,17 Persistent 
hoarseness and neck lump have been previously highlighted as the 
most common symptoms resulting in cancer diagnosis.16-19 These 
symptoms were part of HaNC-RC since its first version. One of 
the new additions to the HaNC-RC v2 is the sore throat symptom. 
This is supported by recent studies, showing unilateral sore throat 
to have a 9.5% positive predictive value in identification of HNC.22 
Indeed, in our multivariate model, patients with unilateral persis-
tent sore throat were 9.7 times more likely to have cancer compared 
with individuals without sore throat. By making these changes, the 
predictive power of the revised calculator, following internal valida-
tion, was 88.6%. This is substantially higher than the ROC of the 
HaN-RC v.1 (77%) and the ROC of the Lau et al, model (79%).16,18
Our study is the first to include patients from all types of clinic 
appointments, not just USOC referrals, to look for significant predic-
tors of HNC. This has also allowed us to assess how many patients 
are diagnosed with cancer per clinic type and how re-triaging using 
the HaNC-RC v2 can improve this number. Triaging patients in the 
manner can result in a number needed to treat (NNT) of four to iden-
tify a cancer (25% cancer yield from USOC clinics), compared with 
the current average number of 12.5.15
The potential benefits of HaNC-RC v.2 can only be realised if GPs 
have the appropriate training and procedures in place to triage pa-
tients to the appropriate specialist clinic. This is echoed by a recent 
study, interviewing HaN consultants in the UK, which highlighted 
that the current system of GP referrals for suspected cancers needs 
to be reviewed due to the number of inappropriate referrals and low 
detection rates, and stressed the need for education of the primary 
care sector in the cancer red flags.23 Risk calculators such as the 
HaNC-RC v.2 could be used as an aid to identify high-risk patients 
seen in the primary care sector, and to support decision-making for 
onward referral to specialist HaN clinics. A similar model has been 
used successfully in the Netherlands for referrals of patients with 
possible prostate cancer, having a positive predictive value of 79% 
and a 100% negative predictive value for clinically significant pros-
tate cancer (Gleason >7).24
On the other hand, a recent survey of UK general practices 
showed that only 36% have access to cancer decision support tools, 
and only 16% are likely to use them.25 Possible reasons for the un-
deruse of such resources include the fact that some normograms 
require investigations that are not available to the primary care 
sector, and that in some cases, several calculators are available, 
with little guidance on which one to use. Whilst the last point has 
been addressed to some degree by the development of the Risk 
Assessment Tools (RAT) and the QCancer score tools which are en-
dorsed by Cancer Research UK and have been incorporated into 
the GP software systems since 2013,10,13,26 they do not yet cover 
all types of cancer, such as HNC. Given the high predictive power 
of our revised calculator, and the fact that it is purely symptoms 
and demographics-based, it could be easily integrated into one of 
the above tools.
In the meantime, another possibility to improve referral routes 
would be for trained healthcare professionals to use the HaNC-RC 
in triage clinics based in the hospital or by telephone interview, with 
subsequent allocation of patients to USOC or more routine appoint-
ment. Finally, whilst improving GP referral to specialist clinics should 
have a substantial impact on how quickly a suspected cancer pa-
tient is diagnosed, health professionals still depend on this person 
seeking an initial appointment at the appropriate time. More work 
thus needs to be done to raise public awareness of the early warn-
ing signs. Given that our calculator is based on demographics and 
symptoms that can be easily understood by non-specialists, there 
is potential to translate it into a tool that patients can use to estab-
lish whether they should seek medical advice, similar to that used in 
prostate cancer risk calculators.
4.3 | Limitations of the study and future directions
One of the limitations of this study is that the calculator was designed 
from data collected from only one region in Scotland which could 
limit the generalisability of the model. Nevertheless, previous study 
has shown directly comparable demographics, symptoms presenta-
tion and cancer detection outcomes between Scottish and English 
cohorts, making the calculator relevant for use across the UK.17 
Additionally, the HaNc-RC v2 has only been internally validated. 
Further work is required on external validation of the HaNC-RC v2, 
and prospective audits of the possible models are needed to estab-
lish the best pathway, detection outcomes and long-term outcomes 
of patients being triaged using the calculator.
It will be also interesting to investigate whether machine learn-
ing techniques can improve further the 88.6% prediction power of 
the HaNC-RC v2. Nevertheless, our multivariable logistic regression 
performed better than the best selected machine learning model in 
the publication by Moore et al, with a sensitivity of 7.7% and a spec-
ificity of 25.8% but their selected probability cut-off used was not 
provided for direct comparisons.19
We hope that despite these limitations, we have generated the 
groundwork for further research in the use of a risk calculator for 
HNC. Beyond further work on validation, we should also consider 
pathways for clinical implementation of the tool.
5  | CONCLUSIONS
Improvement of the detection rate of cancer in the HaN clinics is 
possible with the use of a cancer prediction model. The second 
version of the head and cancer risk calculator has achieved a very 
high prediction power using a combination of significant symptoms, 
patients’ demographics and social history factors. With this high 
prediction power, it has not only significant potential to improve pa-
tients’ outcomes but also contribute to better allocation of NHS re-
sources by redesigning the running of the head and clinics. External 
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validation of the new version of the tool is required as well as trial of 
its use as a triaging aid.
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